Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.47 |
| ▸ | CDK2 | P24941 | 7/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289242 | 0.95 | GSK3B (0.46) | GSK3BCDK2MAPK14CCNA2CCNA1 | |
| SCHEMBL12954163 | 0.90 | GSK3B (0.36) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL13121198 | 0.89 | GSK3B (0.62) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13289428 | 0.88 | GSK3B (0.51) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL12953652 | 0.87 | GSK3B (0.55) | GSK3BCDK2MAPK14MEN1KMT2A | |
| SCHEMBL14546009 | 0.85 | CDK2 (0.46) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13289506 | 0.85 | GSK3B (0.47) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL13289118 | 0.85 | GSK3B (0.56) | GSK3BCDK2CCNA2CCNA1MEN1 | |
| SCHEMBL13289272 | 0.85 | GSK3B (0.48) | GSK3BCDK2MEN1KMT2A | |
| SCHEMBL13289063 | 0.85 | GSK3B (0.45) | GSK3BCDK2CCNA2CCNA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |